RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

NCT00629525 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG: RAD001

Sponsor

Daniel George, MD

Collaborators

[object Object]